4 results
DRS/A
MLYS
Mineralys Therapeutics Inc
29 Dec 22
Draft registration statement (amended)
12:00am
for eight weeks, then, upon withdrawal of study medication, followed for another four weeks.
Baseline Demographics of the Patients Enrolled in Target
DRS/A
MLYS
Mineralys Therapeutics Inc
7 Dec 22
Draft registration statement (amended)
12:00am
.
Baseline Demographics of the Patients Enrolled in Target-HTN
We conducted a pre-planned interim analysis for Part 1 of the trial when approximately
DRS
MLYS
Mineralys Therapeutics Inc
4 Nov 22
Draft registration statement
12:00am
weeks.
- 98 -
Baseline demographics of the patients enrolled in Target-HTN
We conducted a pre-planned interim analysis for Part 1 of the trial
- Prev
- 1
- Next